NeuroPace (NPCE) Revenue & Revenue Breakdown
NeuroPace Revenue Highlights
Latest Revenue (Y)
$65.42M
Latest Revenue (Q)
$18.12M
Main Geography (Y)
Non-US
NeuroPace Revenue by Period
NeuroPace Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $65.42M | 43.72% |
| 2022-12-31 | $45.52M | 0.75% |
| 2021-12-31 | $45.18M | 9.83% |
| 2020-12-31 | $41.14M | 11.27% |
| 2019-12-31 | $36.97M | - |
NeuroPace generated $65.42M in revenue during NA 2023, up 43.72% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
NeuroPace Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $18.12M | 0.62% |
| 2023-12-31 | $18.01M | 9.65% |
| 2023-09-30 | $16.43M | -0.50% |
| 2023-06-30 | $16.51M | 14.08% |
| 2023-03-31 | $14.47M | 13.16% |
| 2022-12-31 | $12.79M | 14.63% |
| 2022-09-30 | $11.16M | 9.38% |
| 2022-06-30 | $10.20M | -10.32% |
| 2022-03-31 | $11.37M | 3.43% |
| 2021-12-31 | $11.00M | 6.36% |
| 2021-09-30 | $10.34M | -18.14% |
| 2021-06-30 | $12.63M | 12.60% |
| 2021-03-31 | $11.22M | 4.32% |
| 2020-12-31 | $10.75M | -15.81% |
| 2020-09-30 | $12.77M | 67.16% |
| 2020-06-30 | $7.64M | -23.41% |
| 2020-03-31 | $9.97M | - |
NeuroPace generated $18.12M in revenue during Q1 2024, up 0.62% compared to the previous quarter, and up 141.72% compared to the same period a year ago.
NeuroPace Revenue Breakdown
NeuroPace Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 |
|---|---|
| Non-US | $100.00K |
NeuroPace's latest annual revenue breakdown by geography, as of Dec 23: Non-US (100.00%).
NeuroPace Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.60B | $753.01M |
| CNMD | CONMED | $1.24B | $332.10M |
| NVRO | Nevro | $425.17M | $101.90M |
| AORT | Artivion | $354.00M | $98.02M |
| GKOS | Glaukos | $314.71M | $95.69M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| ANIK | Anika Therapeutics | $166.66M | $41.92M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SRDX | Surmodics | $132.58M | $30.34M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| IRMD | IRadimed | $65.56M | $17.93M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| CVRX | CVRx | $39.30M | $11.81M |
| OSA | ProSomnus | $27.65M | $7.46M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
NPCE Revenue FAQ
What is NeuroPace’s yearly revenue?
NeuroPace's yearly revenue for 2023 was $65.42M, representing an increase of 43.72% compared to 2022. The company's yearly revenue for 2022 was $45.52M, representing an increase of 0.75% compared to 2021. NPCE's yearly revenue for 2021 was $45.18M, representing an increase of 9.83% compared to 2020.
What is NeuroPace’s quarterly revenue?
NeuroPace's quarterly revenue for Q1 2024 was $18.12M, a 0.62% increase from the previous quarter (Q4 2023), and a 25.23% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $18.01M, a 9.65% increase from the previous quarter (Q3 2023), and a 40.84% increase year-over-year (Q4 2022). NPCE's quarterly revenue for Q3 2023 was $16.43M, a -0.50% decrease from the previous quarter (Q2 2023), and a 47.23% increase year-over-year (Q3 2022).
What is NeuroPace’s revenue growth rate?
NeuroPace's revenue growth rate for the last 3 years (2021-2023) was 44.79%, and for the last 5 years (2019-2023) was 76.95%.